Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 4
1952 1
1953 3
1955 1
1956 3
1957 1
1959 1
1961 2
1962 5
1963 4
1964 4
1965 8
1966 3
1967 4
1968 8
1969 6
1970 5
1971 8
1972 3
1973 7
1974 11
1975 9
1976 13
1977 5
1978 10
1979 18
1980 11
1981 12
1982 11
1983 16
1984 19
1985 23
1986 20
1987 21
1988 29
1989 22
1990 40
1991 35
1992 44
1993 44
1994 52
1995 50
1996 45
1997 44
1998 51
1999 50
2000 66
2001 59
2002 58
2003 68
2004 68
2005 94
2006 107
2007 111
2008 107
2009 120
2010 137
2011 172
2012 172
2013 182
2014 247
2015 306
2016 318
2017 313
2018 371
2019 288
2020 310
2021 347
2022 335
2023 310
2024 118

Text availability

Article attribute

Article type

Publication date

Search Results

5,028 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for and ii simon
Your search for Andrii Simon retrieved no results
Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A. Ferrarotto R, et al. J Clin Oncol. 2023 May 20;41(15):2843-2851. doi: 10.1200/JCO.22.02221. Epub 2023 Mar 10. J Clin Oncol. 2023. PMID: 36898078 Clinical Trial.
PURPOSE: We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). ...The primary end point was objective response rate (ORR) per RECIST 1.1; seco …
PURPOSE: We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients w …
Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Kim J, Schell MJ. Kim J, et al. Oncotarget. 2019 Jul 2;10(42):4255-4261. doi: 10.18632/oncotarget.26981. eCollection 2019 Jul 2. Oncotarget. 2019. PMID: 31303960 Free PMC article.
Simon's two-stage design and the admissible two-stage design have been commonly used in practice for single-arm phase II clinical trials when the primary endpoint is binary. ...The modified design approach provides investigators with an alternative when the s …
Simon's two-stage design and the admissible two-stage design have been commonly used in practice for single-arm phase II …
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury.
Cheng J, Jiang J, He B, Lin WJ, Li Y, Duan J, Li H, Huang X, Cai J, Xie J, Zhang Z, Yang Y, Xu Y, Hu X, Wu M, Zhuo X, Liu Q, Shi Z, Yu P, Rong X, Ye X, Saw PE, Wu LJ, Simone CB 2nd, Chua MLK, Mai HQ, Tang Y. Cheng J, et al. Sci Transl Med. 2023 Feb 22;15(684):eabm6543. doi: 10.1126/scitranslmed.abm6543. Epub 2023 Feb 22. Sci Transl Med. 2023. PMID: 36812346 Clinical Trial.
Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients with RIBI fail to respond to or have contraindications to the first-line treatments of bevacizumab and corticosteroids. Here, we reported a …
Radiation-induced brain injury (RIBI) is a debilitating sequela after radiotherapy to treat head and neck cancer, and 20 to 30% of patients …
The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ, Li XY, Li ZM, Liu ZG, Lin MZ, Zhou H, Yu QW, Zhou J, Zhao C, Chen ZB, Wang XC, Peng JY, Chen QY, Fang WF, Yang YP, Zhang B, Xia LP, Hu PL, Hu WH, Li YJ, Mai HQ, Cai XY. Tang LQ, et al. BMC Med. 2023 Mar 16;21(1):94. doi: 10.1186/s12916-023-02790-1. BMC Med. 2023. PMID: 36927541 Free PMC article. Clinical Trial.
In this study, we aimed to assess the efficacy and safety of apatinib combined with capecitabine as a second-line therapy or beyond for treating RM-NPC patients who failed the first-line platinum-based chemotherapy. METHODS: In this single-arm, phase II study, we enrolled …
In this study, we aimed to assess the efficacy and safety of apatinib combined with capecitabine as a second-line therapy or beyond for trea …
Efficacy of ketamine mouthwash in the management of oral and pharyngeal toxicity associated with head and neck chemoradiotherapy: protocol for a phase II, Simon's two-stage trial.
Koffler D, Eckstein J, Herman J, Martins-Welch D, Seetharamu N, Ghaly M, Kohn N, Potters L, Frank D, Sullivan K, Parashar B. Koffler D, et al. BMJ Open. 2023 Apr 11;13(4):e064809. doi: 10.1136/bmjopen-2022-064809. BMJ Open. 2023. PMID: 37041046 Free PMC article.
These data support our rationale of using ketamine mouthwash to decrease acute toxicity of curative treatment of HNC, the efficacy of which is our aim to elucidate. METHODS AND ANALYSIS: This is a phase II, Simon's two-stage trial. Patients have pathologicall …
These data support our rationale of using ketamine mouthwash to decrease acute toxicity of curative treatment of HNC, the efficacy of which …
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Izmirly P, et al. J Am Coll Cardiol. 2020 Jul 21;76(3):292-302. doi: 10.1016/j.jacc.2020.05.045. J Am Coll Cardiol. 2020. PMID: 32674792 Free PMC article. Clinical Trial.
METHODS: This multicenter, open-label, single-arm, 2-stage clinical trial was designed using Simon's optimal approach. Anti-SSA/Ro-positive mothers with a previous pregnancy complicated by CHB were recruited (n = 19 Stage 1; n = 35 Stage 2). ...
METHODS: This multicenter, open-label, single-arm, 2-stage clinical trial was designed using Simon's optimal approach. Anti-SS …
Optimal two-stage designs for phase II clinical trials.
Simon R. Simon R. Control Clin Trials. 1989 Mar;10(1):1-10. doi: 10.1016/0197-2456(89)90015-9. Control Clin Trials. 1989. PMID: 2702835
The primary objective of a phase II clinical trial of a new drug or regimen is to determine whether it has sufficient biological activity against the disease under study to warrant more extensive development. ...
The primary objective of a phase II clinical trial of a new drug or regimen is to determine whether it has sufficient biological acti …
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer.
Wei W, Ban X, Yang F, Li J, Cheng X, Zhang R, Huang X, Huang Y, Li Q, Qiu Y, Zheng M, Zhu X, Li J. Wei W, et al. J Immunother Cancer. 2022 May;10(5):e004338. doi: 10.1136/jitc-2021-004338. J Immunother Cancer. 2022. PMID: 35623659 Free PMC article. Clinical Trial.
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor affecting tumor angiogenesis and proliferation; sintilimab is an anti-PD-1 monoclonal antibody. METHODS: This was a phase II trial using Simon's two-stage design. This study enrolled patients with …
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor affecting tumor angiogenesis and proliferation; sintilimab is an anti-PD-1 mon …
Composition and function of cytochrome c biogenesis System II.
Simon J, Hederstedt L. Simon J, et al. FEBS J. 2011 Nov;278(22):4179-88. doi: 10.1111/j.1742-4658.2011.08374.x. Epub 2011 Oct 20. FEBS J. 2011. PMID: 21955752 Free article. Review.
System II comprises four (sometimes only three) membrane-bound proteins: CcsA (or ResC) and CcsB (ResB) are the components of the cytochrome c synthase, whereas CcdA and CcsX (ResA) function in the generation of a reduced heme c attachment motif. ...This minireview highlig …
System II comprises four (sometimes only three) membrane-bound proteins: CcsA (or ResC) and CcsB (ResB) are the components of the cyt …
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Aggarwal C, Maity AP, Bauml JM, Long Q, Aleman T, Ciunci C, D'Avella C, Volpe M, Anderson E, Jones LM, Sun L, Singh AP, Marmarelis ME, Cohen RB, Langer CJ, Amaravadi R. Aggarwal C, et al. Oncologist. 2023 Jul 5;28(7):644-e564. doi: 10.1093/oncolo/oyad106. Oncologist. 2023. PMID: 37186063 Free PMC article. Clinical Trial.
BACKGROUND: In RAS-mutant tumors, combined MEK and autophagy inhibition using chloroquine demonstrated synthetic lethality in preclinical studies. This phase II trial evaluated the safety and activity of the MEK inhibitor binimetinib combined with hydroxychloroquine (HCQ) …
BACKGROUND: In RAS-mutant tumors, combined MEK and autophagy inhibition using chloroquine demonstrated synthetic lethality in preclinical st …
5,028 results